IN
INM.US InMed Pharmaceuticals Inc
- Market cap
- USD 8.55M
- P/E
- -
- P/B
- 8.59x
- ROE
- -
- Dividend yield
- 5,049.73%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Sep 2026.
Is INM.US undervalued?
Graham numberThe Graham number of InMed Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
InMed Pharmaceuticals Inc fundamental analysis
No fundamental analysis for InMed Pharmaceuticals Inc yet.
InMed Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About InMed Pharmaceuticals Inc
InMed Pharmaceuticals Inc. operates as a pharmaceutical drug development company in the United States. The company researches and develops cannabinoid-based pharmaceuticals products. Its product candidates include INM-901 for Alzheimer's disease, INM-089 for dry age-related macular degeneration, and INM-755, a cannabinol cream. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceutical…
Full company profileInMed Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
InMed Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.09M | 4.14M | 4.60M | 4.94M | 3.18B | 0.00 |
| Gross Profit | -96.1K | -123K | -123K | -183K | -197K | 544K | 1.40M | 1.10M | 1.71M | 710M | -884K |
| Operating Income | -4.38M | -8.98M | -13.5M | -9.15M | -12.2M | -13.8M | -8.38M | -8.13M | -7.92M | -9.90M | -8.04M |
| EBITDA | -3.36M | -8.86M | -10.3M | -8.76M | -12.1M | -18.1M | -7.34M | -7.06M | -7.26M | -9.19M | -7.16M |
| Net Income | -3.44M | -8.89M | -10.0M | -8.94M | -12.6M | -18.6M | -7.95M | -7.68M | -8.16M | -12.6M | -9.32M |
| EPS | -586 | -1,029 | -964 | -856 | -941 | -16,592 | -649 | -201 | -84 | -30 | -17 |
| Balance Sheet | |||||||||||
| Total Assets | 6.41M | 21.3M | 15.1M | 7.80M | 12.1M | 16.5M | 14.1M | 11.8M | 15.6M | 3.03M | 1.31M |
| Total Liabilities | 284K | 713K | 1.19M | 1.92M | 2.97M | 4.78M | 2.02M | 2.62M | 2.15M | 1.96M | 2.51M |
| Shareholders' Equity | 6.13M | 20.6M | 13.9M | 5.88M | 9.12M | 11.7M | 12.1M | 9.21M | 13.4M | 1.08M | -1.20M |
| Cash & Short-term Investments | 5.16M | 20.1M | 13.7M | 5.85M | 9.16M | 8.01M | 8.91M | 6.57M | 11.1M | 2.23M | 1.13B |
| Total Debt | - | - | - | 317K | 334K | 1.02M | 392K | 963K | 741K | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -2.37M | -3.68M | -8.77M | -7.37M | -9.79M | -15.6M | -7.28M | -6.99M | -7.77M | -8.64M | -4.57M |
| Capital Expenditure | 19.5K | 43.8K | 27.0K | 42.6K | 1.73K | 39.1K | 162K | 9.29K | 0.00 | 3.00 | 0.00 |
| Free Cash Flow | -2.38M | -3.72M | -6.71M | -7.42M | -9.79M | -15.6M | -7.45M | -7.00M | -7.77M | -8.64M | -4.57M |
| Ratios | |||||||||||
| ROE | -56.2% | -43.1% | -72.1% | -152.1% | -138.7% | -159.1% | -65.7% | -83.4% | -60.8% | -1,168.4% | - |
| ROA | -53.7% | -41.6% | -66.4% | -114.6% | -104.6% | -113.0% | -56.3% | -64.9% | -52.4% | -414.5% | -713.9% |
| Net Profit Margin | - | - | - | - | - | -1,707.3% | -192.2% | -166.9% | -165.1% | -0.4% | - |
| Debt to Equity | - | - | - | 0.05x | 0.04x | 0.09x | 0.03x | 0.10x | 0.06x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
InMed Pharmaceuticals Inc dividends
- Dividend yield
- 5,049.73%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | USD 432M | 1,037 | - |
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:10 on Nov 5, 2026.
Who owns InMed Pharmaceuticals Inc
- Insiders 0.06%
- Institutions 53.49%
- Public & others 46.44%
- Shares outstanding 549K
- Free float 3.07M
Top funds holding INM.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| AdvisorShares Pure Cannabis ETF | 16.4K | 1.36% | 0.00% | Feb 2025 |
Top institutions holding INM.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| ADAR1 Capital Management LLC | 800K | 14.56% | 0.00% | Jun 2026 |
| Vivo Capital, LLC | 798K | 14.53% | 0.00% | Jun 2026 |
| Squadron Capital Management LLC | 325K | 5.92% | 0.00% | Jun 2026 |
| Ikarian Capital, LLC | 245K | 4.46% | 0.00% | Jun 2026 |
| Ursa Fund Management, LLC | 126K | 2.29% | 0.00% | Jun 2026 |
| Suvretta Capital Management, LLC | 100K | 1.82% | 0.00% | Jun 2026 |
| BOOTHBAY FUND MANAGEMENT, LLC | 74.2K | 1.35% | 0.00% | Jun 2026 |
| Sabby Management LLC | 45.0K | 0.82% | -79.58% | Jun 2026 |
| Jane Street Group LLC | 43.1K | 0.78% | 0.00% | Jun 2026 |
| VR Adviser, LLC | 32.7K | 0.60% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 26.1K | 0.47% | -44.47% | Jun 2026 |
| SEVEN GRAND MANAGERS, LLC | 25.0K | 0.46% | 0.00% | Jun 2026 |
| Scientech Research LLC | 15.5K | 0.28% | 0.00% | Jun 2026 |
| Crestwood Advisors LLC | 14.9K | 0.27% | 0.00% | Jun 2026 |
| TWO SIGMA SECURITIES, LLC | 10.9K | 0.20% | -41.53% | Jun 2026 |
| Stratos Wealth Partners, LTD | 10.8K | 0.20% | 0.00% | Jun 2026 |
| Private Wealth Management Group LLC | 5.00K | 0.09% | 0.00% | Jun 2026 |
| SBI Securities Co Ltd | 300.00 | 0.01% | 0.00% | Jun 2026 |
| Banque Cantonale Vaudoise | 6.00 | 0.00% | 0.00% | Jun 2026 |
| Federation des caisses Desjardins du Quebec | 2.00 | 0.00% | 0.00% | Jun 2026 |
InMed Pharmaceuticals Inc company profile
- Company name
- InMed Pharmaceuticals Inc
- Ticker
- INM.US
- ISIN
- CA4576377002
- Exchange
- USA Stocks
- Listed since
- Nov 12, 2020
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 6
- Fiscal year end
- June
- Address
- 500 West Georgia Street, Vancouver, BC, Canada, V6B 0M3
- Phone
- 604 669 7207
- Website
- inmedpharma.com
About InMed Pharmaceuticals Inc
InMed Pharmaceuticals Inc. operates as a pharmaceutical drug development company in the United States. The company researches and develops cannabinoid-based pharmaceuticals products. Its product candidates include INM-901 for Alzheimer's disease, INM-089 for dry age-related macular degeneration, and INM-755, a cannabinol cream. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.
InMed Pharmaceuticals Inc management
7- Mr. Eric A. Adams B.S. Chem., M.I.B.President, CEO & Director · born 1964
- Ms. N. Netta JagpalCFO & Corporate Secretary · born 1973
- Mr. Michael Woudenberg P.Eng.Chief Operating Officer · born 1970
- Dr. Eric Chih-Hsien Hsu Ph.D.Senior Vice President of Preclinical Research & Development · born 1970
- Dr. Sazzad Hossain M.Sc., Ph.D.Co-Founder · born 1958
- Mr. Colin ClancyVP of Investor Relations & Corporate Communications
- Mr. Jerry P. GriffinVice President of Sales & Marketing